HTGF invests in novel approach for the treatment of Obesity and Diabetes Type II – perora
September 4, 2013
perora GmbH, a new, privately held biotech company, that was incorporated in June 2013, announced today the closing of its seed venture capital financing round led by High-Tech-Gründerfonds. perora´s operations and headquarters are based in Heidelberg. The company´s management team consists of Dr. Dirk Vetter, Managing Director, and Dr. Kristina Schmidt, Chief Admin and Operations Officer. The proceeds of this round will be used to develop perora´s lead program, a medical device for the treatment of obesity and diabetes type II.
According to WHO estimates, more than 1.4 billion people worldwide are overweight. perora GmbH is an emerging biotech company which is creating a novel non-invasive platform for the treatment of obesity and diabetes type II. The company is built upon its proprietary PNN technology. PNNs, peroral nutrient neutralizers, are polymer compositions optimized for reducing the availability of the caloric load of food after ingestion. In combination with an innovative oral dosage form, a highly convenient and safe approach for weight management is being explored with the goal of providing a unique and effective treatment option.
“perora has an innovative technology platform for developing therapeutic modalities in the underserved and rapidly growing market of weight management,” said Dr. Christian Jung, Investment Manager at HTGF. “perora offers a truly compelling investment opportunity: a unique technology protected by strong intellectual property, regulatory approval as medical device, and an experienced management team. The potential of this emerging company is exciting, and HTGF is very pleased to help develop it further.”
“Support from such an internationally reputed seed investor as HTGF is a strong validation of our technology approach and business model,” commented Dirk Vetter, co-founder and Managing Director of perora GmbH. “The investment will allow us to validate our encouraging results in vivo and to move our innovative non-invasive medical device towards approval.”
About perora GmbH
Perora brought REDIA to market, the first effective medical food for the dietary management of diabetes type 2.
Contact:
perora GmbH
Dr. Dirk Vetter
Im Neuenheimer Feld 518
69120 Heidelberg
dirk.vetter@perora.com
www.perora.com
About High-Tech Gruenderfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Technology, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 573.5 million under management in two funds (EUR 272 million HTGF I, EUR 301.5 million HTGF II).
Contact:
High-Tech Gründerfonds
Dr. Christian Jung
Schlegelstraße 2
53113 Bonn
Tel: +49 (228) 823 001-45
Fax: +49 228 823 000-50
c.jung@high-tech-gruenderfonds.de
www.high-tech-gruenderfonds.de
Stay up to date
Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!
Cultimate Foods raises 2.3 million EUR seed funding from leading Biotech and Foodtech investors to revolutionize the alternative meat industry
Successful Exit for HTGF: DocuWare Announces Acquisition of natif.ai
